​

Halozyme Therapeutics (HALO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HALO Stock Forecast

Halozyme Therapeutics (HALO) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $103.00, with a high of $115.00 and a low of $90.00. This represents a -4.09% decline from the last price of $107.39.

$35 $51 $67 $83 $99 $115 High: $115 Avg: $103 Low: $90 Last Closed Price: $107.39

HALO Stock Rating

Halozyme Therapeutics stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (66.67%), 8 Hold (29.63%), 1 Sell (3.70%), and 0 Strong Sell (0.00%).

Buy
Total 27 1 8 18 Strong Sell Sell Hold Buy Strong Buy

HALO Price Target Upside V Benchmarks

TypeNameUpside
StockHalozyme Therapeutics-4.09%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-417
Avg Price Target-$106.25$87.41
Last Closing Price$107.39$107.39$107.39
Upside/Downside--1.06%-18.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26252--9
Aug, 26243--9
Jul, 262431-10
Jun, 262431-10
May, 262421-9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 10, 2026Wells Fargo$95.00$103.12-7.87%-11.54%
Aug 07, 2026Sean LaamanMorgan Stanley$105.00$98.156.98%-2.23%
Aug 07, 2026Leerink Partners$110.00$85.7628.26%2.43%
Aug 07, 2026H.C. Wainwright$115.00$85.7634.10%7.09%
Jun 03, 2026UBS$90.00$68.7830.85%-16.19%
May 12, 2026Morgan Stanley$93.00$71.1130.78%-13.40%
Apr 29, 2026Mitchell KapoorH.C. Wainwright$95.00$63.8648.76%-11.54%
Apr 21, 2026Morgan Stanley$96.00$69.5737.99%-10.61%
Feb 19, 2026Morgan Stanley$94.00$72.1930.21%-12.47%
Feb 19, 2026Wells Fargo$75.00$73.232.42%-30.16%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 02, 2026H.C. WainwrightBuyBuyhold
Aug 07, 2026Morgan StanleyOverweightOverweighthold
Aug 07, 2026Cowen & Co.BuyBuyhold
Aug 07, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 07, 2026CitigroupOutperformOutperformhold
Aug 07, 2026H.C. WainwrightBuyBuyhold
Jul 21, 2026BenchmarkBuyBuyhold
Jun 16, 2026H.C. WainwrightBuyBuyhold
Jun 03, 2026UBSBuyBuyhold
Apr 29, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.86$1.48$2.13$3.50$2.64---
Avg Forecast$2.68$1.32$2.77$4.13$5.05$6.92$8.33$8.84
High Forecast$2.76$1.41$2.79$4.19$5.35$7.86$8.54$9.06
Low Forecast$2.62$1.28$2.74$4.08$4.72$6.24$7.90$8.63
Surprise %6.72%12.12%-23.10%-15.25%-47.72%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$443.31M$660.12M$829.25M$1.02B$1.40B---
Avg Forecast$443.24M$671.79M$830.53M$1.00B$1.19B$1.47B$1.71B$1.83B
High Forecast$453.46M$708.75M$838.20M$1.02B$1.21B$1.47B$1.72B$1.87B
Low Forecast$434.71M$658.04M$827.36M$990.77M$1.18B$1.46B$1.71B$1.80B
Surprise %0.02%-1.74%-0.15%1.18%17.69%---

Net Income Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$402.71M$202.13M$281.59M$444.09M$316.89M---
Avg Forecast$279.99M$331.72M$281.59M$554.68M$675.23M$946.10M$1.10B$1.19B
High Forecast$335.99M$398.06M$337.91M$562.06M$717.60M$1.05B$1.15B$1.22B
Low Forecast$224.00M$265.38M$225.28M$547.30M$632.86M$837.53M$1.06B$1.16B
Surprise %43.83%-39.07%--19.94%-53.07%---

HALO Forecast FAQ

Is Halozyme Therapeutics stock a buy?

Halozyme Therapeutics stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Halozyme Therapeutics is a favorable investment for most analysts.

What is Halozyme Therapeutics's price target?

Halozyme Therapeutics's price target, set by 27 Wall Street analysts, averages $103 over the next 12 months. The price target range spans from $90 at the low end to $115 at the high end, suggesting a potential -4.09% change from the previous closing price of $107.39.

How does Halozyme Therapeutics stock forecast compare to its benchmarks?

Halozyme Therapeutics's stock forecast shows a -4.09% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Halozyme Therapeutics over the past three months?

  • September 2026: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 22.22% Strong Buy, 44.44% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 20.00% Strong Buy, 40.00% Buy, 30.00% Hold, 10.00% Sell, 0% Strong Sell.

What is Halozyme Therapeutics’s EPS forecast?

Halozyme Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $6.92, marking a 162.12% increase from the reported $2.64 in 2025. Estimates for the following years are $8.33 in 2027, and $8.84 in 2028.

What is Halozyme Therapeutics’s revenue forecast?

Halozyme Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $1.47B, reflecting a 4.91% increase from the reported $1.4B in 2025. The forecast for 2027 is $1.71B, and $1.83B for 2028.

What is Halozyme Therapeutics’s net income forecast?

Halozyme Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $946.1M, representing an 198.56% increase from the reported $316.89M in 2025. Projections indicate $1.1B in 2027, and $1.19B in 2028.